HealthQuiet 25d · day 28
FDA expands Mounjaro's label to include cardiovascular risk reduction
Eli Lilly's tirzepatide drug Mounjaro is now approved to lower heart attack and stroke risk in adults with type 2 diabetes.
What to know
- The FDA approved Mounjaro (tirzepatide) for a new use: reducing cardiovascular risk in adults with type 2 diabetes.
- Trial data showed an 8% lower rate of major heart events compared with Lilly's older drug Trulicity.
- Mounjaro is already the top-prescribed branded type 2 diabetes medicine in the U.S., and the expanded label broadens its clinical and commercial use case.
Eli Lilly and Company DrugmakerU.S. Food and Drug Administration Regulator
The record 10 articles and posts · last 28 days
- summary covers to here · Aug 28, 5:05 PM · 1 piece above arrived after
What people are saying 2 voices from 2 sites · verbatim
- Aug 31
-
So long that the first generation ones should be going generic in the next year or so… which should hopefully bring down the costs.
- Aug 28
-
Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks https://www. independent.co.uk/news/health/ eli-lilly-glp1-drug-mounjaro-fda-heart-disease-b3041208.html?utm_source=flipboard&utm_medium=activitypub Posted into health @ health-Independent